ParikhSGoldsteinAKoenigMKet al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17:689-701
2.
DiMauroSSchonEA.Mitochondrial disorders in the nervous system. Annu Rev Neurosci. 2008;31:91-123.
3.
McFarlandRTaylorRTurnbullDA.Neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829-840.
4.
DiMauroSSchonEACarelliVHiranoM.The clinical maze of mitochondrial neurology. Nat Rev Neurol. 2013;9:429-444.
5.
MitchellPMoyleJ.Chemiosmotic hypothesis of oxidative phosphorylation. Nature. 1967;213:137-139.
HiranoMMartiRFerreiro-BarrosCet al. Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Dev Biol. 2001;12:417-427.
11.
TachibanaMSparmanMSritanaudomchaiHet al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature. 2009;461:367-372.
12.
GilesREBlancHCannHMWallaceDC.Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci U S A. 1980;77:6715-6719.
13.
LangBFGrayMWBurgerG.Mitochondrial genome evolution and the origin of eukaryotes. Annu Rev Genet. 1999;33:351-397.
14.
ChinneryPFHudsonG.Mitochondrial genetics. Br Med Bull. 2013;106:135-159.
15.
RossignolRFaustinBRocherCMalgatMMazatJPLetellierT.Mitochondrial threshold effects. Biochem J. 2003;370:751-762.
16.
VentoJPappaB.Genetic counselling in mitochondrial disease. Neurotherapeutics. 2013;10:243-250.
17.
CreeLMSamuelsDCde Sousa LopesSCet al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet.2008;40:249-254.
18.
MunnichARotigAChretienDCormierVBourgeronT.Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis. 1996;19:521-527.
19.
WolfNISmeitinkJA.Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology. 2002;59:1402-1405.
20.
HaasRHParikhSFalkMJet al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94:16-37.
21.
KogaYPovalkoNNishiokaJKatayamaKKakimotoNMatsuishiT.MELAS and l-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci. 2010;1201:104-110.
22.
PavlakisSGPhillipsPCDiMauroSDe VivoDCRowlandLP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes: a distinctive clinical syndrome. Ann Neurol.1984;16:481-488.
23.
ShoffnerJMLottMTLezzaAMSSeibelPBallingerSWWallaceDC.Myoclonic epilepsy and ragged-red fiber disease (MERRF) are associated with a mitochondrial DNA tRNA Lys mutation. Cell. 1990;61:931-937.
24.
HynynenJKomulainenTTukiainenEet al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl. 2014;20:1402-1412.
25.
PfefferGChinneryPF.Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45:4-16.
FogelBPerlmanS.An approach to the patient with late-onset ataxia. Nat Clin Pract Neurol. 2006;2:629-635.
30.
ChinneryPFElliottCGreenGRet al. The spectrum of hearing loss due to mitochondrial DNA defects. Brain. 2000;123:82-92.
31.
GrönlundMAHonarvarASAnderssonSet al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease. Br J Ophthalmol. 2010;94:121-127.
32.
KearnsTP.External ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy: a newly recognized syndrome. Trans Am Ophthalmol Soc. 1965;63:559-625.
FinstererJ.Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol. 2008;39:223-235.
44.
MedinaLChiTLDeVivoDCHilalSK.MR findings in patients with subacute necrotizing encephalomyelopathy (Leigh Syndrome): correlation with biochemical defect. AJR Am J Roentgenol. 1990;154:1269-1274.
45.
SantorelliFMShanskeSJainKDTickDSchonEADiMauroS.A T>C mutation at nt 8993 of mitochondrial DNA in a child with Leigh syndrome. Neurology. 1994;44:972-974.
46.
FukuharaN.Clinicopathological features of MERRF. Muscle Nerve. 1995;18:S90-S94.
47.
ItoSShiraiWAsahinaMHattoriT.Clinical and brain MR imaging features focusing on the brain stem and cerebellum in patients with myoclonic epilepsy with ragged-red fibers due to mitochondrial A8344G mutation. AJNR Am J Neuroradiol. 2008;29:392-395.
48.
ChinneryPHowellNLightowlersRTurnbullD.Molecular pathology of MELAS and MERRF: the relationship between mutation load and clinical phenotype. Brain. 1997;120:1713-1721.
49.
AlpersBJ.Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neurol Psychiatry. 1931;25:469-505.
50.
HuttenlocherPRSolitareGBAdamsG.Infantile diffuse cerebral degeneration with hepatic cirrhosis. Arch Neurol. 1976;33:186-192.
51.
SanetoRPCohenBHCopelandWCNaviauxRK.Alpers-Huttenlocher syndrome: a review. Pediatr Neurol. 2013;48:167-178.
52.
HakonenAHHeiskanenSJuvonenVet al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet. 2005;77:430-441.
53.
GaroneCTadesseSHiranoM.Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2011;134:3326-3332.
54.
LongoNdi San FilippoCAPasqualiM.Disorders of carnitine transport and carnitine cycle. Am J Med Gen. 2006;142C:77-85.
55.
GrayLRTompkinsSCTaylorEB.Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014;71:2577-2604.
56.
DeLM.Defects of pyruvate metabolism and the Krebs cycle. J Child Neurol. 2002;17:3S26-3S33.
57.
RobinsonBHMacKayNChunKLingM.Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. J Inherit Metab Dis. 1996;19:452-462.
58.
LeeHFLeeHJChiCSTsaiCRChangTKWangCJ.The neurological evolution of Pearson syndrome: case report and literature review. Eur J Paediatr Neurol. 2007;11:208-214.
59.
KhambattaSNguyenDLBeckmanTJWittichCM.Kearns–Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325-332.
60.
CaballeroPECandelaMSÁlvarezCITejerinaAÁ.Chronic progressive external ophthalmoplegia: a report of 6 cases and a review of the literature. Neurologist. 2007;13:33-36.
61.
BouillotSMartin-NegrierMLVitalAet al. Peripheral neuropathy associated with mitochondrial disorders: 8 cases and review of the literature. J Peripher Nerv Syst. 2002;7:213-220.
62.
DistelmaierFKoopmanWJvan den HeuvelLPet al. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain. 2009;132:833-842.
63.
AckrellBA.Cytopathies involving mitochondrial complex II. Mol Aspects Med. 2002;23:369-384.
64.
BorisovVB.Defects in mitochondrial respiratory complexes III and IV, and human pathologies. Mol Aspects Med. 2002;23:385-412.
65.
EmmanueleVLópezLCBerardoAet al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69:978-983.
66.
SetKKWeberARBSerajeeFJAhmMH.Clinical reasoning: siblings with progressive weakness, hypotonia, nystagmus, and hearing loss. Neurology. 2018;90:e625-e631.
67.
KoenigMK.Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol. 2008;38:305-313.
68.
DebrayFGMitchellGAAllardPRobinsonBHHanleyJALambertM.Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis. Clin Chem. 2007;53:916-921.
69.
MoravaEvan den HeuvelLPHolFet al. Mitochondrial disease criteria: diagnostic applications in children. Neurology. 2006;67:1823-1826.
70.
MenzesMPOuvrierRA.Peripheral neuropathy associated with mitochondrial disease in children. Dev Med Child Neurol. 2012:54:407-414.
71.
GropmanAL.Neuroimaging in mitochondrial disorders. Neurotherapeutics. 2013;10:273-285.
72.
LindaSLundITorbergsenTAaslyJMellgrenSIBorudOMonstadP.Mitochondrial diseases and myopathies: a series of muscle biopsy specimens with ultrastructural changes in the mitochondria. Ultrastruct Pathol. 1992;16:263-275.
73.
TaylorRWSchaeferAMBarronMJMcFarlandRTurnbullDM.The diagnosis of mitochondrial muscle disease. Neuromuscular Disord. 2004:14:237-245.
74.
AlstonCLRochaMCLaxNZTurnbullDMTaylorRW.The genetics and pathology of mitochondrial disease. J Pathol. 2017;241:236-250.
75.
BourgeoisJMTampolskyMA.Pathology of skeletal muscle in mitochondrial disorders. Mitochondrion. 2004;4:441-452.
ChinneryPMajamaaKTurnbullDThorburnD.Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2006;1:CD004426.
78.
DiMauroSHiranoMSchonEA.Approaches to the treatment of mitochondrial diseases. Muscle Nerve. 2006;34:265-283.
79.
DanhauserKSmeitinkJAFreisingerPet al. Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease. J Inherit Metab Dis. 2015;38:467-475.
80.
KogaYMAkitaYMNishiokaJet al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64:710-712.
81.
RodriguezMCMacDonaldJRMahoneyDJPariseGBealMFTarnopolskyMA.Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007;35:235-242.
82.
TarnopolskyMABealMF.Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49:561-574.
83.
TarnopolskyMARahaS.Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc. 2005;37:2086-2093.
84.
MarriageBClandininMTGlerumDM.Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc. 2003;103:1029-1038.
85.
MarriageBJClandininMTMacdonaldIMGlerumDM.Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab. 2004;81:263-272.
86.
MahoneyDJPariseGTarnopolskyMA.Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr Opin Clin Nutr Metab Care. 2002;5:619-629.
87.
KlopstockTYu-Wai-ManPDimitriadisKet al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134:2677-2686.
88.
KogaYAkitaYNishiokaJ.MELAS and L-arginine therapy. Mitochondrion. 2007;7:133-139.
89.
AnielloMSMartinoDPetruzzellaVet al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord. 2008;23:114-118.
90.
JeppesenTDSchwartzMOlsenDBet al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006;129:3402-3412.
91.
TaivassaloTShoubridgeEAChenJet al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol. 2001;50:133-141.
92.
BatesMGDBourkeJPGiordanoCd’ AmatiGTurnbullDMTaylorRW. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J. 2012;33:3023-3033.
93.
GobuPKarthikeyanBPrasathASanthoshSBalachanderJ.Kearns Sayre syndrome (KSS)—a rare cause for cardiac pacing. Indian Pacing Electrophysiol J. 2010;10:547-550.
